Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effectiveness of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus infection and virologic failure to direct-acting antivirals.

Medicina clinica - 23 Jul 2021

Ruiz-Boy Sonia, Rodriguez-Reyes Montserrat, Sotoca-Momblona Jose Miguel

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminoisobutyric Acids
Share to Carbamates
Share to Cyclopropanes
Share to Drug Combinations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heterocyclic Compounds, 4 or More Rings

Share to Lactams, Macrocyclic

Share to Quinoxalines

Share to Sofosbuvir

Source

Identifiers

PMID: 32807510
DOI: 10.1016/j.medcli.2020.05.054

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effectiveness of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus infection and virologic failure to direct-acting antivirals.PMID 32807510Read ↗

Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus.Semantic proximity Read ↗

Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C.Semantic proximity Read ↗

Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R).Semantic proximity Read ↗

Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

A randomized-controlled trial of SOF/VEL/VOX with or without ribavirin for retreatment of chronic hepatitis C.Semantic proximity Read ↗

Real-World Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir in Treatment Naive and Experienced Chronic Hepatitis C Patients: A Single-Center ExperienceSemantic proximity Read ↗

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.Semantic proximity Read ↗

Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics.Semantic proximity Read ↗

Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C.Semantic proximity Read ↗

Real World Efficacy and Safety of Sofosbuvir + Velpatasvir + Voxilaprevir in Romanian Patients with Genotype 1b HCV Infection Non-reponders to DAAs Therapy.Semantic proximity Read ↗

Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1.Semantic proximity Read ↗

Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.